Search research articles
Contact Us
Filters
Showing results (911-920 of 973) with videos related to
Page
of 98
Sort By:
NPJ Precision Oncology
|
February 13, 2023
Survival improvement for patients with metastatic colorectal cancer over twenty years
Fadl A Zeineddine, Mohammad A Zeineddine, Abdelrahman Yousef, et al.
Cancer Research Communications
|
December 12, 2023
Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination
Kristen Simmons, Jane V Thomas, Kaysia Ludford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2008
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head
Gauri R Varadhachary, Robert A Wolff, Christopher H Crane, et al.
Oncology (Williston Park, N.Y.)
|
February 24, 2001
NCCN Practice Guidelines for Breast Cancer
R W Carlson, B O Anderson, W Bensinger, et al.
NPJ Precision Oncology
|
February 3, 2024
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
Biorxiv : the Preprint Server for Biology
|
August 30, 2023
Integrated spatial transcriptomics and lipidomics of precursor lesions of pancreatic cancer identifies enrichment of long chain sulfatide biosynthesis as an early metabolic alteration
Marta Sans, Yihui Chen, Fredrik I Thege, et al.
JCO Precision Oncology
|
September 11, 2020
Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer
Eugene J Koay, Matthew H G Katz, Huamin Wang, et al.
Journal for Immunotherapy of Cancer
|
August 25, 2022
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Benny Johnson, Cara L Haymaker, Edwin R Parra, et al.
Cancer Biomarkers : Section a of Disease Markers
|
September 13, 2024
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab
Yehia I Mohamed, Sunyoung S Lee, Tarik Demir, et al.
Research Square
|
August 23, 2023
Impact of <i>KRAS</i> Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
Page
of 98
Search research articles
Search
Showing results (911-920 of 973) with videos related to
Sort By:
Page
of 98
NPJ Precision Oncology
|
February 13, 2023
Survival improvement for patients with metastatic colorectal cancer over twenty years
Fadl A Zeineddine, Mohammad A Zeineddine, Abdelrahman Yousef, et al.
Cancer Research Communications
|
December 12, 2023
Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination
Kristen Simmons, Jane V Thomas, Kaysia Ludford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2008
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head
Gauri R Varadhachary, Robert A Wolff, Christopher H Crane, et al.
Oncology (Williston Park, N.Y.)
|
February 24, 2001
NCCN Practice Guidelines for Breast Cancer
R W Carlson, B O Anderson, W Bensinger, et al.
NPJ Precision Oncology
|
February 3, 2024
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
Biorxiv : the Preprint Server for Biology
|
August 30, 2023
Integrated spatial transcriptomics and lipidomics of precursor lesions of pancreatic cancer identifies enrichment of long chain sulfatide biosynthesis as an early metabolic alteration
Marta Sans, Yihui Chen, Fredrik I Thege, et al.
JCO Precision Oncology
|
September 11, 2020
Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer
Eugene J Koay, Matthew H G Katz, Huamin Wang, et al.
Journal for Immunotherapy of Cancer
|
August 25, 2022
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Benny Johnson, Cara L Haymaker, Edwin R Parra, et al.
Cancer Biomarkers : Section a of Disease Markers
|
September 13, 2024
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab
Yehia I Mohamed, Sunyoung S Lee, Tarik Demir, et al.
Research Square
|
August 23, 2023
Impact of <i>KRAS</i> Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
Page
of 98